MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that its Chief Scientific Officer, Dr. Arun Upadhyay, will be a featured speaker at the prestigious 4th Annual Dry AMD Therapeutic Development Summit. The event is scheduled to take place from November 14-16, 2023, in Boston, Massachusetts.
Dr. Upadhyay’s presentation, titled “Understanding the Complexity of Dry AMD: A Multifactorial Perspective,” will provide insights into the underlying causes of dry age-related macular degeneration (AMD), a condition affecting approximately 1 million individuals in the United States alone. His session is planned for November 16, 2023, from 11 to 11:30 a.m. ET.
The summit will bring together experts across biotech and pharma who are actively developing drugs with the potential to revolutionize the treatment of dry AMD. Dr. Upadhyay’s contribution to this discourse is particularly significant given Ocugen’s ongoing efforts in this field.
Ocugen is currently developing OCU410, a modifier gene therapy candidate utilizing the nuclear hormone receptor gene RORA, for the treatment of geographic atrophy—an advanced form of dry AMD. The firm is optimistic about the potential of OCU410 to address the unmet medical need in this category. As part of its development plan, Ocugen intends to dose patients in the Phase 1/2 trial by the end of 2023.
With Dr. Upadhyay’s expertise at the forefront, Ocugen continues to position itself as a leader in the therapeutic development landscape for dry AMD, offering promising prospects for investors.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.